1. Tomic D, Shaw JE, Magliano DJ. The burden and risks of emerging complications of diabetes mellitus. Nature Reviews Endocrinology. 2022;18(9):525-539. [DOI:10.1038/s41574-022-00690-7]

2. Carracher AM, Marathe PH, Close KL. International diabetes federation 2017. Wiley Online Library; 2018. [DOI:10.1111/1753-0407.12644]

3. Khan RMM, Chua ZJY, Tan JC, Yang Y, Liao Z, Zhao Y. From pre-diabetes to diabetes: diagnosis, treatments and translational research. Medicina. 2019;55(9):546. [DOI:10.3390/medicina55090546]

4. Esteghamati A, Etemad K, Koohpayehzadeh J, Abbasi M, Meysamie A, Noshad S, et al. Trends in the prevalence of diabetes and impaired fasting glucose in association with obesity in Iran: 2005-2011. Diabetes research and clinical practice. 2014;103(2):319-327. [DOI:10.1016/j.diabres.2013.12.034]

5. Buraczynska M, Buraczynska K, Zukowski P, Ksiazek A. Interleukin-4 Gene Intron 3 VNTR Polymorphism in Type 2 Diabetes Patients with Peripheral Neuropathy. Immunol Invest. 2018 Feb;47(2):146-153. eng. Epub 20171128. doi:10.1080/08820139.2017.1407334. Cited in: Pubmed; PMID 29182400. [DOI:10.1080/08820139.2017.1407334]

6. Mirzaei M, Rahmaninan M, Mirzaei M, Nadjarzadeh A, Dehghani Tafti AA. Epidemiology of diabetes mellitus, pre-diabetes, undiagnosed and uncontrolled diabetes in Central Iran: results from Yazd health study. BMC public health. 2020;20:1-9. [DOI:10.1186/s12889-020-8267-y]

7. Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. The lancet. 2017;389(10085):2239-2251. [DOI:10.1016/S0140-6736(17)30058-2]

8. Pillon NJ, Loos RJ, Marshall SM, Zierath JR. Metabolic consequences of obesity and type 2 diabetes: Balancing genes and environment for personalized care. Cell. 2021;184(6):1530-1544. [DOI:10.1016/j.cell.2021.02.012]

9. Zhang D, Tang Z, Huang H, Zhou G, Cui C, Weng Y, et al. Metabolic regulation of gene expression by histone lactylation. Nature. 2019;574(7779):575-580. [DOI:10.1038/s41586-019-1678-1]

10. De Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS letters. 2008;582(1):97-105. [DOI:10.1016/j.febslet.2007.11.057]

11. Oguntibeju OO. Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links. International journal of physiology, pathophysiology and pharmacology. 2019;11(3):45.

12. Khdair SI, Al-Naimat OS, Jarrar W, Al-Qerem W, Khudeir FA. The Influence of TNF-α, IL-6, TGF-β1, IFN-γ, IL-10 Polymorphisms on Predisposition to Diabetes Mellitus among Jordanian Patients. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders). 2023;23(5):681-691. [DOI:10.2174/1871530322666220827143530]

13. Creusot RJ, Chang P, Healey DG, Tcherepanova IY, Nicolette CA, Fathman CG. A Short Pulse of IL-4 Delivered by DCs Electroporated With Modified mRNA Can Both Prevent and Treat Autoimmune Diabetes in NOD Mice. Molecular Therapy. 2010 2010/12/01/;18(12):2112-2120. doi: https://doi.org/10.1038/mt.2010.146 [DOI:10.1038/mt.2010.146.]

14. Michurina S, Stafeev I, Beloglazova I, Zubkova E, Mamontova E, Kopylov A, et al. Regulation of glucose transport in adipocytes by interleukin-4. Journal of Interferon & Cytokine Research. 2022;42(3):127-136. [DOI:10.1089/jir.2021.0213]

15. Kannourakis G, Abbas A. The role of cytokines in the pathogenesis of Langerhans cell histiocytosis. The British journal of cancer Supplement. 1994;23:S37.

16. Salimi S, Mohammadoo-Khorasani M, Yaghmaei M, Mokhtari M, Moossavi M. Possible association of IL-4 VNTR polymorphism with susceptibility to preeclampsia. BioMed Research International. 2014;2014. [DOI:10.1155/2014/497031]

17. Phu TA, Ng M, Vu NK, Bouchareychas L, Raffai RL. IL-4 polarized human macrophage exosomes control cardiometabolic inflammation and diabetes in obesity. Molecular Therapy. 2022 2022/06/01/;30(6):2274-2297. doi: https://doi.org/10.1016/j.ymthe.2022.03.008 [DOI:10.1016/j.ymthe.2022.03.008.]

18. Ibrahimi M, Moossavi M, Mojarad EN, Musavi M, Mohammadoo-Khorasani M, Shahsavari Z. Positive correlation between interleukin-1 receptor antagonist gene 86bp VNTR polymorphism and colorectal cancer susceptibility: a case-control study. Immunologic research. 2019;67:151-156. [DOI:10.1007/s12026-018-9034-3]

19. Ali R, Saber L, Al-Harbi A. A novel association between IL1-Ra (receptor antagonist) gene polymorphism and T1DM in Al-Madina Al-Mounawra. European Review for Medical and Pharmacological Sciences. 2015;19(19):3701-3708.

20. Mohammadoo-Khorasani M, Salimi S, Tabatabai E, Sandoughi M, Zakeri Z. Association of interleukin-1 receptor antagonist gene 86bp VNTR polymorphism with systemic lupus erythematosus in south east of Iran. Zahedan Journal of Research in Medical Sciences. 2013;16(12).

21. Badr E, Assar M, Elshayeb EI, Fath El-Bab S, El-Kousy S. A preliminary study of the relation between IL-4 and hypertension in type II diabetes mellitus. Molecular biology reports. 2018;45(6):1967-1972. [DOI:10.1007/s11033-018-4349-7]

22. Tripathi A, Shukla S, Tripathi J, Saket R, Kol S, Mishra P, et al. Association of genetic polymorphism of inflammatory genes (IL-1β and IL-4) with diabetes type 2. Enliven: J Genet Mol Cell Biol. 2015;1(1):004. [DOI:10.18650/2379-5700.21001]

23. Daneshmandi S, Pourfathollah AA, Kazemi Arababadi M, Hasan Shahi GH, Rezaeian M, Asyabanha Rezaee M. Evaluation of relation between IL-4 and IFN- γ polymorphisms and type 2 diabetes [Research(Original)]. Journal of Mazandaran University of Medical Sciences. 2008;18(66):35-41. eng.

24. Hassan MM. The significance of interleukin 4 (IL-4)(590-C/T) gene polymorphism in Iraqi patients with type 2 diabetes mellitus: A case-control study. Res J Pharm Technol. 2019;12(11):5133-5137. [DOI:10.5958/0974-360X.2019.00889.8]

25. Ho K-T, Shiau M-Y, Chang Y-H, Chen C-M, Yang S-C, Huang C-N. Association of interleukin-4 promoter polymorphisms in Taiwanese patients with type 2 diabetes mellitus. Metabolism. 2010 2010/12/01/;59(12):1717-1722. doi: https://doi.org/10.1016/j.metabol.2010.04.010 [DOI:10.1016/j.metabol.2010.04.010.]

26. Ali R, El‐Said A, El‐Baz H, Settin A. Ethnic variation of IL‐4 intron 3 VNTR gene polymorphism; its association with type 2 diabetes mellitus and its complication (neuropathy) in Egyptian subjects. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2018;177(7):635-640. [DOI:10.1002/ajmg.b.32647]

27. Kazemi AM. Interleukin-4 gene polymorphisms in type 2 diabetic patients with nephropathy. Iranian Journal of Kidney Diseases. 2010;4(4):302-306.

28. Basol N, Inanir A, Yigit S, Karakus N, Kaya SU. High Association of IL-4 Gene Intron 3 VNTR Polymorphism with Diabetic Peripheral Neuropathy. Journal of Molecular Neuroscience. 2013 2013/10/01;51(2):437-441. doi:10.1007/s12031-013-0048-y. [DOI:10.1007/s12031-013-0048-y]

29. Neelofar K, Ahmad J, Ahmad A, Alam K. Study of IL4-590C/T and IL6-174G/C Gene Polymorphisms in Type 2 Diabetic Patients With Chronic Kidney Disease in North Indian Population. Journal of Cellular Biochemistry. 2017;118(7):1803-1809. doi: https://doi.org/10.1002/jcb.25853 [DOI:10.1002/jcb.25853.]

30. Arababadi MK, Nosratabadi R, Hassanshahi G, Yaghini N, Pooladvand V, Shamsizadeh A, et al. Nephropathic complication of type-2 diabetes is following pattern of autoimmune diseases? Diabetes research and clinical practice. 2010;87(1):33-37. [DOI:10.1016/j.diabres.2009.09.027]